Problems and Pitfalls of Identifying Remyelination in Multiple Sclerosis.

Regenerative medicines that promote remyelination in multiple sclerosis (MS) are making the transition from laboratory to clinical trials. While animal models provide the experimental flexibility to analyze mechanisms of remyelination, here we discuss the challenges in understanding where and how remyelination occurs in MS.

Keywords

Animals, Models, Animal, Multiple Sclerosis, Myelin Sheath, Oligodendroglia, Regenerative Medicine, Remyelination

Journal Title

Cell Stem Cell

Journal ISSN

1934-5909
1875-9777

Volume Title

26

Publisher

Elsevier

Publisher DOI

https://doi.org/10.1016/j.stem.2020.03.017

Rights and licensing

Except where otherwised noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International

Sponsorship

MULTIPLE SCLEROSIS SOCIETY (50)
Wellcome Trust (203151/Z/16/Z)
European Research Council (771411)
Medical Research Council (MC_PC_12009)
Medical Research Council (G0701476)
Medical Research Council (MC_PC_17230)
Medical Research Council (MR/R015635/1)

The authors acknowledge the following support: The UK Multiple Sclerosis Society (RTK, CZ, RJMF), The Adelson Medical Research Foundation (DSR, DEB, RJMF), Intramural Research Program of NINDS/NIH (DSR), European Research Council (ERC) under the European Union Horizon 2020 Re- search and Innovation Program (RTK), The Lister Institute (RTK), and a core support grant from the Wellcome and MRC to the Wellcome-Medical Research Council Cambridge Stem Cell Institute (RTK, RJMF).

Collections

University of Cambridge Research Outputs (Articles and Conferences)